2020 Fiscal Year Final Research Report

Establishment of the multipurpose biomarker which targetted specific secretor exosome in esophageal cancer

Research Project

PDF

Project/Area Number	18K08675
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 55020:Digestive surgery-related
Research Institution	Mie University
Principal Investigator	Ohi Masaki 三重大学, 医学部附属病院, 准教授 (40418752)
Co-Investigator(Kenkyū-buntansha)	問山裕二三重大学, 医学系研究科, 教授 (00422824) 楠正人三重大学, 医学系研究科, 寄附講座大学教員 (50192026) 吉山繁幸三重大学, 医学系研究科, リサーチアソシエイト (60444436) 安田裕美三重大学, 医学部附属病院, 助教 (60586767) 荒木俊光三重大学, 医学系研究科, リサーチアソシエイト (70343217)
Project Period (FY)	2018-04-01 – 2021-03-31
Keywords	食道癌 / パネル / 内視鏡治療 / 低侵襲手術
Outline of Final Research Achievements	Esophageal cancer is a disease with high medical demand because the number of mortality and morbidity do not decrease even after the development of treatment. However, after radical surgery for esophageal cancer, the QOL of patients is often impaired, such as decreased food intake, weight loss, diarrhea, and reflux symptoms. It is extremely significant from the viewpoint of medical expenses as well as contributing to the health of the patient. In this study, we identified protein X that is specifically expressed in Exosome that is secreted specifically for esophageal cancer, and clarified some clinical significance.
Free Research Field	消化管外科
Academic Significance and Societal Importance of the Research Achievements	食道癌特異的に分泌されるExosomeに特異的に発現する蛋白Xを同定し、その蛋白X陽性Exosomeに包埋された遺伝子情報を解析することで、食道癌診断特異的パネルを作成し、非侵襲的なLiquid biopsyによる食道癌患者の診断から治療にわたる戦略を検証し、低侵襲的な治療の適応や予後因子などを予測できれば、内視鏡治療、低侵襲手術などの適応を早期に決定でき、国民の予後改善、治療後のQOLを改善する点でも医療費の観点からも極めて学術的意義や社会的意義は高いと思われる。